Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

Massimo Galli, Spinello Antinori, Fabiola Atzeni, Luca Meroni, Agostino Riva, Carlo A. Scirè, Fulvio Adorni, Luca Quartuccio, Marco Sebastiani, Paolo Airò, Laura Bazzichi, Francesco Cristini, Valerio Del Bono, Andreina Manfredi, Ombretta Viapiana, Francesco De Rosa, Ennio Favalli, Enzo Petrelli, Carlo Salvarani, Marcello Govoni & 14 others Silvia Corcione, Rossana Scrivo, Loredana Sarmati, Adriano Lazzarin, Walter Grassi, Claudio Mastroianni, Giovanni Battista Gaeta, Gianfranco Ferraccioli, Maurizio Cutolo, Salvatore De Vita, Giovanni Lapadula, Marco Matucci-Cerinic, Orlando Armignacco, Piercarlo Sarzi-Puttini

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

Original languageEnglish
Pages (from-to)1018-1028
Number of pages11
JournalClinical and Experimental Rheumatology
Volume35
Issue number6
Publication statusPublished - Nov 1 2017

Fingerprint

Fungal Lung Diseases
Rheumatoid Arthritis
Antirheumatic Agents
Lung
Infection
Invasive Pulmonary Aspergillosis
Coccidioidomycosis
Pneumocystis carinii
Cryptococcosis
Histoplasmosis
Pneumocystis Pneumonia
Rheumatic Diseases
Japan
Therapeutics

Keywords

  • Fungal infection
  • Pneumonia
  • Recommendations
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. / Galli, Massimo; Antinori, Spinello; Atzeni, Fabiola; Meroni, Luca; Riva, Agostino; Scirè, Carlo A.; Adorni, Fulvio; Quartuccio, Luca; Sebastiani, Marco; Airò, Paolo; Bazzichi, Laura; Cristini, Francesco; Del Bono, Valerio; Manfredi, Andreina; Viapiana, Ombretta; De Rosa, Francesco; Favalli, Ennio; Petrelli, Enzo; Salvarani, Carlo; Govoni, Marcello; Corcione, Silvia; Scrivo, Rossana; Sarmati, Loredana; Lazzarin, Adriano; Grassi, Walter; Mastroianni, Claudio; Gaeta, Giovanni Battista; Ferraccioli, Gianfranco; Cutolo, Maurizio; De Vita, Salvatore; Lapadula, Giovanni; Matucci-Cerinic, Marco; Armignacco, Orlando; Sarzi-Puttini, Piercarlo.

In: Clinical and Experimental Rheumatology, Vol. 35, No. 6, 01.11.2017, p. 1018-1028.

Research output: Contribution to journalReview article

Galli, M, Antinori, S, Atzeni, F, Meroni, L, Riva, A, Scirè, CA, Adorni, F, Quartuccio, L, Sebastiani, M, Airò, P, Bazzichi, L, Cristini, F, Del Bono, V, Manfredi, A, Viapiana, O, De Rosa, F, Favalli, E, Petrelli, E, Salvarani, C, Govoni, M, Corcione, S, Scrivo, R, Sarmati, L, Lazzarin, A, Grassi, W, Mastroianni, C, Gaeta, GB, Ferraccioli, G, Cutolo, M, De Vita, S, Lapadula, G, Matucci-Cerinic, M, Armignacco, O & Sarzi-Puttini, P 2017, 'Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis', Clinical and Experimental Rheumatology, vol. 35, no. 6, pp. 1018-1028.
Galli, Massimo ; Antinori, Spinello ; Atzeni, Fabiola ; Meroni, Luca ; Riva, Agostino ; Scirè, Carlo A. ; Adorni, Fulvio ; Quartuccio, Luca ; Sebastiani, Marco ; Airò, Paolo ; Bazzichi, Laura ; Cristini, Francesco ; Del Bono, Valerio ; Manfredi, Andreina ; Viapiana, Ombretta ; De Rosa, Francesco ; Favalli, Ennio ; Petrelli, Enzo ; Salvarani, Carlo ; Govoni, Marcello ; Corcione, Silvia ; Scrivo, Rossana ; Sarmati, Loredana ; Lazzarin, Adriano ; Grassi, Walter ; Mastroianni, Claudio ; Gaeta, Giovanni Battista ; Ferraccioli, Gianfranco ; Cutolo, Maurizio ; De Vita, Salvatore ; Lapadula, Giovanni ; Matucci-Cerinic, Marco ; Armignacco, Orlando ; Sarzi-Puttini, Piercarlo. / Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. In: Clinical and Experimental Rheumatology. 2017 ; Vol. 35, No. 6. pp. 1018-1028.
@article{ba3a46568b8f4799a8432ed2e20e52fa,
title = "Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis",
abstract = "Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).",
keywords = "Fungal infection, Pneumonia, Recommendations, Rheumatoid arthritis",
author = "Massimo Galli and Spinello Antinori and Fabiola Atzeni and Luca Meroni and Agostino Riva and Scir{\`e}, {Carlo A.} and Fulvio Adorni and Luca Quartuccio and Marco Sebastiani and Paolo Air{\`o} and Laura Bazzichi and Francesco Cristini and {Del Bono}, Valerio and Andreina Manfredi and Ombretta Viapiana and {De Rosa}, Francesco and Ennio Favalli and Enzo Petrelli and Carlo Salvarani and Marcello Govoni and Silvia Corcione and Rossana Scrivo and Loredana Sarmati and Adriano Lazzarin and Walter Grassi and Claudio Mastroianni and Gaeta, {Giovanni Battista} and Gianfranco Ferraccioli and Maurizio Cutolo and {De Vita}, Salvatore and Giovanni Lapadula and Marco Matucci-Cerinic and Orlando Armignacco and Piercarlo Sarzi-Puttini",
year = "2017",
month = "11",
day = "1",
language = "English",
volume = "35",
pages = "1018--1028",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "6",

}

TY - JOUR

T1 - Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis

AU - Galli, Massimo

AU - Antinori, Spinello

AU - Atzeni, Fabiola

AU - Meroni, Luca

AU - Riva, Agostino

AU - Scirè, Carlo A.

AU - Adorni, Fulvio

AU - Quartuccio, Luca

AU - Sebastiani, Marco

AU - Airò, Paolo

AU - Bazzichi, Laura

AU - Cristini, Francesco

AU - Del Bono, Valerio

AU - Manfredi, Andreina

AU - Viapiana, Ombretta

AU - De Rosa, Francesco

AU - Favalli, Ennio

AU - Petrelli, Enzo

AU - Salvarani, Carlo

AU - Govoni, Marcello

AU - Corcione, Silvia

AU - Scrivo, Rossana

AU - Sarmati, Loredana

AU - Lazzarin, Adriano

AU - Grassi, Walter

AU - Mastroianni, Claudio

AU - Gaeta, Giovanni Battista

AU - Ferraccioli, Gianfranco

AU - Cutolo, Maurizio

AU - De Vita, Salvatore

AU - Lapadula, Giovanni

AU - Matucci-Cerinic, Marco

AU - Armignacco, Orlando

AU - Sarzi-Puttini, Piercarlo

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

AB - Often life-threatening pulmonary fungal infections (PFIs) can occur in patients with rheumatoid arthritis (RA) receiving disease-modifying anti-rheumatic drugs (DMARDs). Most of the data concerning PFIs in RA patients come from case reports and retrospective case series. Of the five most widely described PFIs, Pneumocystis jirovecii pneumonia (PJP) has rarely been seen outside Japan, pulmonary cryptococcosis has been diagnosed in only a small number of patients worldwide, pulmonary coccidioidomycosis has almost only been observed in endemic areas, the limited number of cases of pulmonary histoplasmosis have mainly occurred in the USA, and the rare cases of invasive pulmonary aspergillosis have only been encountered in leukopenic patients. Many aspects of the prophylaxis, diagnosis and treatment of PFIs in RA patients remain to be defined, as does the role of each DMARD in increasing the risk of infection, and the possibility of resuming biological and non-biological DMARD treatment after the infection has been cured. The recommendations for the management of PFIs described in this paper are the product of a consensus procedure promoted by the Italian group for the Study and Management of Infections in Patients with Rheumatic Diseases (the ISMIR group).

KW - Fungal infection

KW - Pneumonia

KW - Recommendations

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=85040565526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040565526&partnerID=8YFLogxK

M3 - Review article

VL - 35

SP - 1018

EP - 1028

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 6

ER -